|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A 4-mm punch biopsy showed a poorly differentiated tumor with cells that were positive for CAM 5.2 and cytokeratin 20 in a dotlike paranuclear pattern and negative for cytokeratin 5/6, human melanoma black 45, and leukocyte common antigen.
|
29763480 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This is due to changes in the cause of tumor microenvironment with crackdown of neovascularization and evoking apoptosis process as assessed by CAM, corneal vascularization and apoptotic hallmarks in 8f treated cells.
|
29133037 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Meanwhile, the anti-neovascularization activity of HA-ES2-AF in vivo was studied by CAM assay, and the targeting of HA-ES2-AF to tumour tissue was studied by bioimaging techniques.
|
30170067 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we observed that riluzole reduced the tumor growth in <i>in vivo</i> CAM assay, suggesting it could be a possible synergistic drug for the treatment of glioblastoma.
|
29228563 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When compared with the clinically established HDAC inhibitor vorinostat, the novel dual-mode compound animacroxam exhibited superior antitumoral efficacy <i>in vitro</i> Animacroxam also reduced the tumor size of TGCT tumors <i>in vivo</i>, as evidenced by performing xenograft experiments on tumor bearing chorioallantoic membranes of fertilizes chicken eggs (CAM assay).
|
28838999 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, we proved that compound 3d inhibited the tumor growth effectively through inducing cell apoptosis without affecting CAM normal angiogenesis.
|
28634389 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed that overexpression of SPARC in SK-N-BE(2) and NB1691 cells reduced radiation induced angiogenesis in an in vivo mouse dorsal skin model and an ex vivo chicken CAM (chorioallantoic-membrane) model and also reduced tumor size in subcutaneous mouse tumor models of NB.
|
27498840 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is well known that tumor microenvironment plays a vital role in drug resistance and cell adhesion-mediated drug resistance (CAM-DR), a form of de novo drug resistance.
|
24703465 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, the CE7 epitope of L1-CAM on a variety of tumors may be amenable to targeting by CE7R T cells, making it a promising target for adoptive immunotherapy.
|
24509172 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RKIP downregulation was also associated with an increased vascularization of the tumors in vivo using a CAM assay.
|
23527098 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proangiogenic potential of NAP was identified using shell less CAM, rat cornea and tumor on CAM assays.
|
23000338 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The return to origin probability (RTOP) and its related CAM expression ratio in tumors, so-called "tumor self-seeding", gradually decreased with increased tumor size, and approached the 3D Pólya random walk constant (0.340537) in a periodic structure.
|
22889191 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The sarcomatoid component of the tumor expressed several types of cytokeratins, such as AE1/AE3, CK 5/6, 34betaE12, and CAM 5.2.
|
21602664 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, capsaicin potently suppressed the growth of H69 human SCLC tumors in vivo as ascertained by CAM assays and nude mice models.
|
20421925 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, patients with tumors showing high L1-CAM expression had a shorter disease-free and overall survival.
|
19787228 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In order to investigate its anti-tumor mechanism, we studied the effects of YSL on CaM protein expression and mRNA level, PI3K activity, PI3K regulatory subunit p85 protein expression and mRNA level, and the mRNA level of PI3K catalytic subunits p110alpha and p110gamma in human hepatocellular carcinoma BEL-7402 xenograft tumors in nude mice.
|
17546603 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies.
|
17952127 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) is not only involved in maintaining normal tissue architecture, but also acts as a tumor suppressor in several experimental systems where loss of CEACAM1 expression results in enhanced tumor-cell growth and tumorigenicity.
|
11964043 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CEACAM1 (also known as biliary glycoprotein, C-CAM or CD66a) is a cell adhesion molecule of the immunoglobulin family behaving as a tumor inhibitory protein in colon, prostate, liver, endometrial and breast cancers.
|
11313949 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On the basis of these results, we conclude that hNr-CAM is a valid target for potential gene therapy of glioblastoma tumors.
|
10697494 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To test this hypothesis, we analyzed pairs of tumor tissue and corresponding normal-appearing lung tissue from 51 patients with non-small cell lung cancer (NSCLC) and 43 cell lines to determine expression profiles of L-form C-CAM1 and S-form C-CAM1 using reverse transcription-PCR.
|
10955775 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our approach to this technology has been to design a mutant of human carboxypeptidase A (hCPA1-T268G) which is capable of hydrolyzing in vivo stable prodrugs of MTX and targeting this enzyme to tumors on an Ep-CAM1-specific antibody, ING1.
|
9893962 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PC-3 tumors in nude mice exhibited 2 to 3-week lag in tumor growth curves after a single Ad-C-CAM1 injection.
|
10226564 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Results from Northern blot and immunofluorescence analyses of tumor nodules demonstrated that C-CAM1 decreased rather than enhanced phenotypic differentiation and induced ultrastructural and morphological changes that occurred independently of tumor suppression.
|
10359532 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, while C-CAM gene therapy may have immediate application in prostate cancer treatment, the knowledge to be learned from mechanistic studies of C-CAM1-mediated tumor suppression may also help us design better strategies for prevention and treatment for prostate cancer.
|
10597733 |
1999 |